Compare Biogen Inc (BIIB) vs Cigna Corp (CI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Cigna Corp — how do they compare? Biogen Inc trades at $207.69 (market cap $30.13B), while Cigna Corp trades at $277.72 (market cap $73.56B). The key difference: Cigna Corp is far larger — about 2.4× Biogen Inc's market cap, and Cigna Corp pays a 2.24% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | CI | |
|---|---|---|
Market Cap | $30.13B | $73.56B |
Sector | Health | Health |
52-Week High | $216.63 | $311.00 |
52-Week Low | $128.93 | $244.41 |
Enterprise Value | $37.20B | $98.27B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Cigna (CI) trades at $275.4, down 1.08% today, with technical indicators signaling a bearish short-term trend. The stock shows strong fundamentals, including a low P/E of 11.51 and consistent earnings beats, with Q2 2026 EPS of $7.78 exceeding expectations. Recent news highlights raised 2026 EPS guidance to at least $30.45, driven by growth in health services and insurance segments.
The outlook is positive, supported by analyst consensus with a $338.90 price target and 73.68% buy ratings. Key risks include competitive pressures and regulatory changes in healthcare. The valuation gap presents an opportunity, but investors should monitor medical cost trends and execution of growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
